This is our final presentation of Summer School at High Tech Campus, Eindhoven, about our product DrugArt's business plan. We won the Best Entrepreneurial Team, at EIT ICT Labs Summer School, Wellbeing Innovation Camp 2013.

1. EITeam4
Hypertension &
Drug Dose Monitoring

2. 1.000.000.000
Hypertension Patients
350.000.000
Overdosed
9.400.000
Deaths
10.000.000.000 €
Annual Savings
Problems

3. Patients
Doctors
Pharma Companies
Insurance Companies
Decision Makers

4. Over Dosage
Timing of Dosage
Reliable & 24/7 Monitoring
Reliability of Intake
It may be possible to reduce the number
and dosage of drugs.
“
ESH/ESC Guidelines for the management of arterial hypertension, 2013
10 Billion
ProblemsMarket(€) Decision Makers
Targeted Problems
Ineffectivity of Drugs

5. Over Dosage
Timing of Dosage
Reliability of Intake
Reliable & 24/7 Monitoring
10 Billion
70 Million
ProblemsMarket(€)
Targeted Problems
Decision Makers
Ineffectivity of Drugs

6. Over Dosage
Timing of Dosage
Reliability of Intake
“ The importance of adequate BP control over the
entire 24-hour period.
Journal of Managed Care Pharmacy, William B. White 2007
Reliable & 24/7 Monitoring
10 Billion
70 Million
1.5 Billion
ProblemsMarket(€)
Targeted Problems
Decision Makers
Ineffectivity of Drugs

7. Over Dosage
Timing of Dosage
Reliability of Intake
More than 50% of all medicines are prescribed,
dispensed or sold inappropriately
May 2010, WHO
“
10 Billion
70 Million
1.5 Billion
5 Billion
Reliable & 24/7 Monitoring
ProblemsMarket(€)
Targeted Problems
Decision Makers
Ineffectivity of Drugs

8. Over Dosage
Timing of Dosage
Ineffectivity of Drugs
Reliability of Intake
Half of all patients fail to take medicines
correctly.
May 2010, WHO
“
10 Billion
70 Million
1.5 Billion
5 Billion
2 Billion
Reliable & 24/7 Monitoring
ProblemsMarket(€)
Targeted Problems
Decision Makers

9. Clinical
Platform
1
2
Optimal Dose
Intake Monitoring
Blood Pressure
Heart Beat Rate
Drug Dose Info
Physical Exercise
Value Proposition

10. Strategy

11. Clinics
End User
Care
Cardiologists
Publications
ISH
WHO
ASH
ESH
Strategy

12. Clinics
End User
Care
Cardiologists
Publications
ISH
WHO
ASH
ESH
Strategy
Insurance
Companies
(Joint Insurance)
Allianz Aetna
AXA PPP

13. Clinics
End User
Care
Cardiologists
Publications
ISH
WHO
ASH
ESH
Strategy
Pharma
Companies
Bayer
Teva
Novartis
Merck & Co.
Insurance
Companies
(Joint Insurance)
Allianz Aetna
AXA PPP

14. Clinics
End User
Care
Cardiologists
Publications
ISH
WHO
ASH
ESH
Strategy
Pharma
Companies
Bayer
Teva
Novartis
Merck & Co.
Insurance
Companies
(Joint Insurance)
Allianz Aetna
AXA PPP
GP
End User
Prevention

15. Clinics
End User
Care
GP
Insurance
Companies
(Joint Insurance)
Pharma
Companies
Cardiologists
End User
Prevention
Revenue Streams
Worldwide

16. Clinics
End User
Care
GP
Insurance
Companies
(Joint Insurance)
Pharma
Companies
Cardiologists
End User
Prevention
1
Revenue Streams
Worldwide

17. Clinics
End User
Care
GP
Insurance
Companies
(Joint Insurance)
Pharma
Companies
Cardiologists
End User
Prevention
1
Revenue Streams
2
Worldwide

18. Clinics
End User
Care
GP
Insurance
Companies
(Joint Insurance)
Pharma
Companies
Cardiologists
End User
Prevention
1
3
Revenue Streams
2
Worldwide

19. Go to India

20. 1.2 billion
population
Go to India

21. 1.2 billion
population
40 million
potential
customers
Go to India

22. 1.2 billion
population
40 million
potential
customers
10% penetration
in 10 years
Go to India

23. 1.2 billion
population
40 million
potential
customers
10% penetration
in 10 years
Go to India
Hypertension is a well-known chronic
disease

24. Clinics
End User
Care
GP
Pharma
Companies
Cardiologists
1
3
Go to India
2

25. -30
65
160
255
350
Roadmap & Financials
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Profit Cumulative Operating Profit
million €
0
Cumulative Operating Profit with Pharmas
ROI

26. Risk Analysis
0
25
50
75
100
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Technical Value Proposition Competition Go 2 Market

28. Costs 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
R&D 3000000 2000000 1000000 1000000 500000 500000 250000 250000 250000 250000 250000
Patenting 100000 100000 100000 0 0 0 0 0 0 0 0
Marketing &
Market
research
2000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000
Platform
running cost
10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000
Salaries 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000
Logistics 50000 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000
Misc Market
Penetration
Cost
5000000 10000000 10000000 10000000 25000000 25000000 10000000 10000000 10000000 10000000 10000000
Cost Breakdown

29. Nurse Visiting
Hospital Visiting
Clinical Cost
Data Security
Privacy
Drug Coverage
Side Effects
Connection
Report
Life Style
Service Cost
Our Product Proteus Traditional
high
low
Competition